Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2018-02-14
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of cixutumumab when given
together with temsirolimus and to see how well they work in treating patients with breast
cancer that has recurred (come back) at or near the same place as the original (primary)
tumor or has spread to other places in the body. Monoclonal antibodies, such as cixutumumab,
can block tumor growth in different ways by targeting certain cells. Temsirolimus may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving
cixutumumab together with temsirolimus may be a better treatment for breast cancer.